Rocket Pharmaceuticals (RCKT) Non-Current Debt (2014)

Rocket Pharmaceuticals (RCKT) reported Non-Current Debt of $2.6 million for Q4 2014.

Rocket Pharmaceuticals (RCKT) Non-Current Debt (2014) Analysis & Trends

Rocket Pharmaceuticals (RCKT) has 1 years of Non-Current Debt data on file, last reported at $2.6 million in Q4 2014.

For the quarter ending Q4 2014, Non-Current Debt changed N/A year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2014 stood at $2.6 million (changed N/A YoY), and the FY2014 full-year result was $2.6 million, changed N/A from the prior year.
Non-Current Debt steadied at $2.6 million in Q4 2014.
In the past five years, Non-Current Debt ranged from a high of $2.6 million in Q4 2014 to a low of $2.6 million in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Rocket Pharmaceuticals	357.93 Mn	357.93 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2014	2.55 Mn